![]() VIARTIS
|
||||||
PARKINSON'S DISEASE NEWS |
||||||
|
Parkinson's Disease News covers all significant new research, reports, books, and resources concerning Parkinson's Disease. Articles are chosen on the basis of their medical significance or potential interest. Our overwhelming priority is the facts, regardless of whether they contradict prevailing views or vested interests. Analysis and further information are provided either to explain the background or implications, or to balance misleading claims. If you notice errors or inadequacies, or dispute what is written, or want to propose articles, please e-mail [email protected].
2nd April 2014 - New clinical trial
ISRADIPINE BEING TESTED FOR PARKINSON'S DISEASE
The basis for the clinical trial is that data from large studies found that there was a lower incidence of Parkinson's Disease among those people who took Israpidine. However, when Isradioine was tested in Phase II clinical trials in people who had Parkinson's Disease Isradipine caused side effects. The most common adverse events were peripheral edema and dizziness. Isradipine also failed to have any significant effect on Parkinson's Disease symptoms. For more information go to the Phase II clinical trial In order to effectively treat Parkinson's Disease effectively dopamine formation must be increased but, even in theory, calcium channel blockers can not do that. For more news go to Parkinson's Disease News.
|
|
||||
![]() |
||||||
�2006-2014 Viartis | ||||||
2015-08-07 22:59:29 | ||||||
[email protected] |